No abstract

No abstract

SUPPLEMENT ABSTRACTSResults: Fifty-seven patients were eligible for this retrospective analysis. Median age at BEGEV therapy was 36.2 years (range 18-70), and the median time from frontline therapy to the first cycle of BEGEV was 5 months. At the end of BEGEV, 50 patients achieved a complete response (CR, 87.7%), with an overall response rate of 89.5%. Fifty-five patients harvested CD34+ cells and 50 ones underwent ASCT with 49 patients in CR at the end of the therapeutic pathway. With a median follow-up of 31.4 months, 7 CR patients had disease relapse, yielding an estimated disease-free survival of 73.9% at 34 months. The estimated 2-year progression-free survival was 83.4% (median not reached). Six patients had an early BEGEV discontinuation due toxicity, but they were still able to perform ASCT with a CR.Conclusions: Real-life data on BEGEV regimen as first salvage setting showed a relevant rate of objective responses and a limited myelotoxicity with no impairment of a subsequent mobilization of peripheral blood stem cells. BEGEV regimen was well tolerated, and reversible adverse events were the most common ones.